Bright Pink Assess Your Risk™: a novel interactive tool for breast and ovarian cancer prevention (Preprint)

2021 ◽  
Author(s):  
Elizabeth A Hibler ◽  
Angela J Fought ◽  
Kiarri N Kershaw ◽  
Rebecca Molsberry ◽  
Virginia Nowakowski ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Assessment ◽  
Family History ◽  
Cancer Risk ◽  
Ovarian Cancer Risk ◽  
Age Group ◽  
Breast And Ovarian Cancer ◽  
Nccn Guidelines ◽  
Bright Pink ◽  
Race Ethnicity

BACKGROUND The lifetime risk of breast and ovarian cancer is significantly higher among women with genetic susceptibility or strong family history. However, current practices may identify only 10% of asymptomatic carriers of susceptibility genes. Bright Pink developed the Assess Your Risk (AYR) tool to estimate breast and ovarian cancer risk through a user-friendly, informative online quiz. OBJECTIVE The objectives of this work are to present the AYR tool, describe the AYR users, and compare classification using the AYR tool to breast and ovarian cancer genetic testing guidelines. METHODS The AYR tool includes 26 questions based on the National Cancer Center Network (NCCN) guidelines and factors from other commonly used risk assessment tools. We included all women who completed AYR between November 2018 and January 2019 with the exception of self-reported cancer or no knowledge of family history. We conducted univariate analyses and compared the AYR tool to NCCN criteria using measures of validity along with McNemar's Test. RESULTS There were 143,657 AYR completions, and most participants were either at increased or average risk for breast cancer or ovarian cancer (95.6%). Using the NCCN guidelines as the gold standard, the estimated sensitivity and specificity for the AYR was 100% and 89.9%, respectively (McNemar’s p= <0.001). Specificity improved when considering the additional questions asked by the AYR. However, we did observe some variation by race-ethnicity and age group. We found the lowest observed specificity was for Asian race (85.9%) and the 30-39 year age group (87.6%) for the AYR compared to NCCN criteria. CONCLUSIONS These results demonstrate that Bright Pink’s AYR is an accurate tool for identifying women at increased risk of breast and ovarian cancer. However, future studies should validate the tool longitudinally, considering the variation observed by race-ethnicity and age on breast and ovarian cancer risk assessment.

scholarly journals Bright Pink Assess Your Risk™: a novel interactive tool for breast and ovarian cancer risk assessment (Preprint)

10.2196/29124 ◽  
2021 ◽  
Author(s):  
Elizabeth A Hibler ◽  
Angela J Fought ◽  
Kiarri N Kershaw ◽  
Rebecca Molsberry ◽  
Virginia Nowakowski ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Cancer Risk Assessment ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Interactive Tool ◽  
Bright Pink

Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1513-1513
Author(s):  
Leif W. Ellisen ◽  
Allison W. Kurian ◽  
Andrea J Desmond ◽  
Meredith Mills ◽  
Stephen E Lincoln ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Clinical Impact ◽  
Gene Panel ◽  
Cancer Risk Assessment ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Panel Testing ◽  
Gene Panel Testing

scholarly journals Hereditary breast and ovarian cancer: risk assessment in minority women and provider knowledge gaps

2016 ◽  
Vol 14 (6) ◽  
pp. 261-267 ◽  
Author(s):  
Nancy Paris ◽  
Sheryl Gabram-Mendola ◽  
Alice Kerber ◽  
Jean O'Connor ◽  
Barbara Crane ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Minority Women ◽  
Cancer Risk Assessment ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Knowledge Gaps ◽  
Provider Knowledge

scholarly journals Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment

JAMA Oncology ◽  
2015 ◽  
Vol 1 (7) ◽  
pp. 943 ◽  
Author(s):  
Andrea Desmond ◽  
Allison W. Kurian ◽  
Michele Gabree ◽  
Meredith A. Mills ◽  
Michael J. Anderson ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Cancer Risk Assessment ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Panel Testing ◽  
Multigene Panel Testing ◽  
Multigene Panel

Ovarian Cancer Risk Assessment

2006 ◽  
Vol 107 (Supplement) ◽  
pp. 11S ◽  
Author(s):  
Deborah A. Ronco ◽  
John P. Geisler ◽  
K J. Manahan
Keyword(s):  
Ovarian Cancer ◽  
Risk Assessment ◽  
Cancer Risk ◽  
Cancer Risk Assessment ◽  
Ovarian Cancer Risk

scholarly journals A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

2007 ◽  
Vol 107 (2) ◽  
pp. 289-301 ◽  
Author(s):  
Claire E. Wakefield ◽  
Bettina Meiser ◽  
Judi Homewood ◽  
Michelle Peate ◽  
Alan Taylor ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Randomized Controlled Trial ◽  
Genetic Testing ◽  
Cancer Risk ◽  
Decision Aid ◽  
Controlled Trial ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Randomized Controlled

scholarly journals Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer

2000 ◽  
Vol 29 (5) ◽  
pp. 799-802 ◽  
Author(s):  
A Tavani ◽  
E Ricci ◽  
C La Vecchia ◽  
M Surace ◽  
G Benzi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Reproductive Factors ◽  
Ovarian Cancer Risk ◽  
History Of

scholarly journals Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer

2018 ◽  
Vol 10 (2) ◽  
pp. 337-346 ◽  
Author(s):  
Mary Kathleen Ladd ◽  
Beth N Peshkin ◽  
Leigha Senter ◽  
Shari Baldinger ◽  
Claudine Isaacs ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Genetic Counseling ◽  
Cancer Risk ◽  
Prophylactic Surgery ◽  
Ovarian Cancer Risk ◽  
Breast And Ovarian Cancer ◽  
Affective Factors ◽  
Risk Reducing

Abstract Risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) are increasingly used to reduce breast and ovarian cancer risk following BRCA1/BRCA2 testing. However, little is known about how genetic counseling influences decisions about these surgeries. Although previous studies have examined intentions prior to counseling, few have examined RRM and RRSO intentions in the critical window between genetic counseling and test result disclosure. Previous research has indicated that intentions at this time point predict subsequent uptake of surgery, suggesting that much decision-making has taken place prior to result disclosure. This period may be a critical time to better understand the drivers of prophylactic surgery intentions. The aim of this study was to examine predictors of RRM and RRSO intentions. We hypothesized that variables from the Health Belief Model would predict intentions, and we also examined the role of affective factors. Participants were 187 women, age 21–75, who received genetic counseling for hereditary breast and ovarian cancer. We utilized multiple logistic regression to identify independent predictors of intentions. 49.2% and 61.3% of participants reported intentions for RRM and RRSO, respectively. Variables associated with RRM intentions include: newly diagnosed with breast cancer (OR = 3.63, 95% CI = 1.20–11.04), perceived breast cancer risk (OR = 1.46, 95% CI = 1.17–1.81), perceived pros (OR = 1.79, 95% CI = 1.38–2.32) and cons of RRM (OR = 0.81, 95% CI = 0.65–0.996), and decision conflict (OR = 0.80, 95% CI = 0.66–0.98). Variables associated with RRSO intentions include: proband status (OR = 0.28, 95% CI = 0.09–0.89), perceived pros (OR = 1.35, 95% CI = 1.11–1.63) and cons of RRSO (OR = 0.72, 95% CI = 0.59–0.89), and ambiguity aversion (OR = 0.79, 95% CI = 0.65–0.95). These data provide support for the role of genetic counseling in fostering informed decisions about risk management, and suggest that the role of uncertainty should be explored further.

Sign in / Sign up

Export Citation Format

Share Document